[A13-04] Ingenol mebutate - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

Last updated 15.04.2013

Project no.:
A13-04

Commission:
Commission awarded on 14.01.2013 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Skin and hair

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

15.04.2013

Added benefit of ingenol mebutate is not proven

Manufacturer's dossier did not contain any relevant data for the comparison with diclofenac/hyaluronic acid gel

Current document

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.